# Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer

> **NCT05083780** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Changhoon Yoo** · enrollment: 40 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Chlorphenesin Carbamate, Hydroxychloroquine

## Key facts

- **NCT ID:** NCT05083780
- **Lead sponsor:** Changhoon Yoo
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-30
- **Primary completion:** 2025-12-28
- **Final completion:** 2026-12-30
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-04-16

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05083780

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05083780, "Hydroxychloroquine and Chlorphenesin Carbamate in Combination With mFOLFIRINOX in Pancreatic Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05083780. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*